Dr. Arnaud Foussat is Chief Executive Officer at Alderaan Biotechnology, a company developing novel therapies to treat cancer by targeting cells from the immune system. Arnaud has over 18 years of experience in immunotherapy research and development.
Arnaud Foussat is also Operating Partner at AdBio partners. Before joining AdBio Partners, Arnaud was Chief Scientific Officer of TxCell (acquired by Sangamo in 2018), where he developed Regulatory T-cell based cell therapy for chronic inflammatory diseases.
A graduate from Institut Pasteur of Paris, Arnaud Foussat obtained his Ph.D. degree in Immunology from the University of Paris VII in 2000.